Investors who own more than 5% of a class must file a Schedule 13D or 13G. Every filing for 230031106 since 12/18/2024, newest first.
| Filer | % of Class | Filed | |
|---|---|---|---|
|
Biotechnology Value Fund L P
13G/A
Amendment 8
|
10.0% |
8/14/2026
Event 6/30/2026
|
|
| Biotechnology Value Fund L P | 5.7% | ||
| BVF I GP LLC | 5.7% | ||
| Biotechnology Value Fund II LP | 3.5% | ||
| BVF II GP LLC | 3.5% | ||
| Biotechnology Value Trading Fund OS LP | 0.6% | ||
| BVF Partners OS Ltd. | 0.6% | ||
| BVF GP Holdings LLC | 9.2% | ||
| BVF Partners L P/IL | 10.0% | ||
| BVF Inc/IL | 10.0% | ||
| Lampert Mark N | 10.0% | ||
| Price T Rowe Associates Inc /MD/ 13G | 6.2% |
8/14/2026
Event 6/30/2026
|
|
| State Street Corp 13G | 6.0% |
8/7/2026
Event 6/30/2026
|
|
|
Biotechnology Value Fund L P
13G/A
Amendment 7
|
10.0% |
5/15/2026
Event 3/31/2026
|
|
| Biotechnology Value Fund L P | 5.8% | ||
| BVF I GP LLC | 5.8% | ||
| Biotechnology Value Fund II LP | 3.7% | ||
| BVF II GP LLC | 3.7% | ||
| Biotechnology Value Trading Fund OS LP | 0.4% | ||
| BVF Partners OS Ltd. | 0.4% | ||
| BVF GP Holdings LLC | 9.4% | ||
| BVF Partners L P/IL | 10.0% | ||
| BVF Inc/IL | 10.0% | ||
| Lampert Mark N | 10.0% | ||
| Vanguard Group Inc 13G/A Amendment 1 | 0% |
3/26/2026
Event 3/13/2026
|
|
|
Kynam Capital Management, LP
13G
|
5.3% |
3/4/2026
Event 12/31/2025
|
|
| Kynam Capital Management, LP | 5.3% | ||
| Kynam Capital Management GP, LLC | 5.3% | ||
| Yue Tang | 5.3% | ||
|
Biotechnology Value Fund L P
13G/A
Amendment 6
|
10.0% |
2/17/2026
Event 12/31/2025
|
|
| Biotechnology Value Fund L P | 5.6% | ||
| BVF I GP LLC | 5.6% | ||
| Biotechnology Value Fund II LP | 3.8% | ||
| BVF II GP LLC | 3.8% | ||
| Biotechnology Value Trading Fund OS LP | 0.4% | ||
| BVF Partners OS Ltd. | 0.4% | ||
| BVF GP Holdings LLC | 9.4% | ||
| BVF Partners L P/IL | 10.0% | ||
| BVF Inc/IL | 10.0% | ||
| Lampert Mark N | 10.0% | ||
| Vanguard Group Inc 13G | 5.6% |
1/30/2026
Event 12/31/2025
|
|
|
Citadel Advisors LLC
13G/A
Amendment 1
|
3.4% |
11/14/2025
Event 9/30/2025
|
|
| Citadel Advisors LLC | 3.1% | ||
| Citadel Advisors Holdings LP | 3.1% | ||
| Citadel GP LLC | 3.1% | ||
| Citadel Securities LLC | 0.3% | ||
| Citadel Securities Group LP | 0.3% | ||
| Citadel Securities GP LLC | 0.3% | ||
| Kenneth Griffin | 3.4% | ||
|
Lynx1 Capital Management LP
13G/A
Amendment 2
|
9.8% |
11/14/2025
Event 9/30/2025
|
|
| LYNX1 Capital Management LP | 9.8% | ||
| Weston Nichols | 9.8% | ||
|
James E. Flynn
13G/A
Amendment 1
|
4.95% |
11/13/2025
Event 9/30/2025
|
|
| Deerfield Mgmt, L.P. | 4.95% | ||
| Deerfield Management Company, L.P. | 4.95% | ||
| Deerfield Partners, L.P. | 4.95% | ||
| James E. Flynn | 4.95% | ||
| Vanguard Group Inc 13G/A Amendment 2 | 4.98% |
10/30/2025
Event 9/30/2025
|
|
|
Lynx1 Capital Management LP
13G/A
Amendment 1
|
14.5% |
10/10/2025
Event 10/8/2025
|
|
| Lynx1 Capital Management LP | 14.5% | ||
| Weston Nichols | 14.5% | ||
|
Lynx1 Capital Management LP
13G
|
7.5% |
8/14/2025
Event 6/30/2025
|
|
| Lynx1 Capital Management LP | 7.5% | ||
| Weston Nichols | 7.5% | ||
|
Citadel Advisors LLC
13G
|
5.1% |
8/6/2025
Event 7/30/2025
|
|
| Citadel Advisors LLC | 4.3% | ||
| Citadel Advisors Holdings LP | 4.3% | ||
| Citadel GP LLC | 4.3% | ||
| Citadel Securities LLC | 0.8% | ||
| Citadel Securities Group LP | 0.8% | ||
| Citadel Securities GP LLC | 0.8% | ||
| Kenneth Griffin | 5.1% | ||
|
Franklin Resources, Inc.
13G/A
Amendment 1
|
3.8% |
10/31/2024
Event 9/30/2024
|
|
| Franklin Resources, Inc. | 3.8% | ||
| Charles B. Johnson | 0% | ||
| Rupert H. Johnson, Jr. | 0% |
| Period | Filings | Shares, Excl. Options | Value, Excl. Options |
|---|---|---|---|
| 2026 Q3 | 4 | 4.48 k | $68.7 k |
| 2026 Q2 | 193 | 72.4 M | $1.35 B |
| 2026 Q1 | 179 | 65.6 M | $931 M |
| 2025 Q4 | 160 | 63.2 M | $654 M |
| 2025 Q3 | 149 | 61.1 M | $363 M |
| 2025 Q2 | 151 | 62.6 M | $472 M |
| 2025 Q1 | 154 | 64.7 M | $490 M |
| 2024 Q4 | 153 | 65.6 M | $799 M |
| 2024 Q3 | 146 | 65.0 M | $1.09 B |
| 2024 Q2 | 142 | 63.8 M | $1.11 B |
| 2024 Q1 | 120 | 41.7 M | $711 M |
| 2023 Q4 | 120 | 38.0 M | $387 M |
| 2023 Q3 | 112 | 38.3 M | $346 M |
| 2023 Q2 | 110 | 36.9 M | $397 M |
| 2023 Q1 | 107 | 32.3 M | $330 M |
| 2022 Q4 | 102 | 38.3 M | $404 M |
| 2022 Q3 | 104 | 37.0 M | $475 M |
| 2022 Q2 | 91 | 37.6 M | $482 M |
| 2022 Q1 | 85 | 36.9 M | $386 M |
| 2021 Q4 | 79 | 36.4 M | $560 M |
| 2021 Q3 | 68 | 33.9 M | $762 M |
| 2021 Q2 | 73 | 32.3 M | $829 M |
| 2021 Q1 | 71 | 31.3 M | $1.30 B |